Eur. Respir. J., 7, 579 (1994) (on order). |
Trends Pharm., Sci., 12, 19 (1991) (on order). |
Thorax, 46, 512 (1991) (on order). |
J. Pharmacol. Exp. Ther., 266, 306 (1993) (on order). |
Br. J. Pharmacol., 112, 332 (1994) (on order). |
Nature Medicine, 1, 244 (1994) (on order). |
Clin. Exp. Immunol., 100, 126 (1995) (on order). |
Barnes et al.; “Theoplhylline in the Management of Asthma: Time for Reappraisal”; Eur. Respir. J., vol. 7, pp. 579-591 (1994) U.K. |
Nicholson et al.; “Differential Modulation of Tissue Function and Therapeutic Potential of Selective Inhibitors of Cyclic Nucleotide Phosphodiesterase Isoenzymes”; TIPS (1991), vol. 12, pp. 19-27, U.K. |
Torphy et al.; “Phosphodiesterase Inhibitors: New Opportunities for the Treatment of Asthma”; Thorax, vol. 46, pp. 512-523 (1991) U.S. |
Underwood et al.; “Inhibition of Antigen-Induced Bronchoconstriction and Eosinophil Infiltration in the Guinea Pig by the Cyclic AMP-Specific Phosphodiesterase Inhibitor, Rolimpram”; J. Pharmacol. Exp. Ther., vol. 266 No. 1, pp. 306-313 (1993) U.S. |
Teixeira et al.; “Effects of Phosphodiesterase Isoenzyme Inhibitors on Cutaneous Inflammation in the Guinea-Pig”; Br. J. Pharmacol., vol. 112, pp. 332-340 (1994) U.S. |
Sommer et al.; “The Antidepressant Rolipram Suppresses Cytokine Production and Prevents Autoimmune Encephalomyelitis”;Nature Medicine, vol. 1, pp. 244-249 (1995) U.S. |
Sekut et al.; “Anti-Inflammatory Activity of Phosphodiesterase (PDE)-IV Inhibitors in a...and Chronic Models of Inflammation”,Clin. Exp. Immunol., vol. 100, pp. 126-132 (1995) U.S. |